Profound Medical Corp

Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for image-guided ablation of diseased tissue. Its lead product, the TULSA-PRO system, combines MRI, robotically driven transurethral sweeping thermal ultrasound, and closed-loop temperature feedback control to ablate the whole gland or a physician-defined region of malignant or benign prostate tissue. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland, and is headquartered in Mississauga, Canada.

PROF▲

Profound Medical Shares Gain 8.11% Over 52 Weeks Despite Q1 Drop in Hedge Fund Holdings

Profound Medical Corp. closed at $6.87 per share on June 18, 2026, with a one-month return of 0.51% and a 52-week gain of 8.11%. Grow Funds highlighted the company in its first-quarter 2026 investor letter, noting its TULSA-PRO system is installed at 78 marquee hospitals with a pipeline of over 110 systems. The fund also pointed to higher hospital reimbursement compared to competitive procedures and favorable results from the Captain Trial versus radical prostatectomy. However, hedge fund holdings in Profound Medical fell to 6 at the end of the first quarter from 10 in the prior quarter, and the stock was not among the 40 most popular hedge fund stocks heading into 2026.

PROF ▲

Insider Monkey·88dRead more →